Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
Top Page
MiNK Therapeutics
(NASDAQ:INKT)
40Underperform
Positive Factors
Clinical Trial Data
Biomarker data from the Phase 2 study demonstrate increased immune modulation in refractory gastroesophageal cancer, showing increases in immune cell infiltration, T-cell activation, and pro-inflammatory biomarkers linked to cytotoxic activity.
Patient Enrollment
Patient enrollment in the Phase 2 IST testing AGENT-797 in patients with second-line gastric cancer has exceeded expectations, and initial data will be presented at a medical meeting.
Negative Factors
Financial Concerns
Reducing price target to $4/share to account for risks associated with potential future dilution.
MiNK Therapeutics (INKT) vs. S&P 500 (SPY)
Market Cap
$30.95M
Dividend YieldN/A
Average Volume (3M)36.36K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS Growth46.74%
CountryUS
Employees31
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.86
Shares Outstanding3,963,040
10 Day Avg. Volume9,418
30 Day Avg. Volume36,359
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.00Price Target Upside163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MiNK Therapeutics Business Overview & Revenue Model
Company DescriptionMiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
How the Company Makes MoneyMiNK Therapeutics generates revenue primarily through the development and commercialization of its proprietary iNKT cell therapy platforms. Revenue streams include licensing agreements, research collaborations, and potential milestone payments from pharmaceutical partners who are interested in utilizing MiNK's technology for drug development. Additionally, the company may earn income through government grants or public funding for research and development initiatives. Strategic partnerships and alliances with larger biotech companies can also play a significant role in supporting MiNK's financial growth by sharing resources and expanding market reach.
MiNK Therapeutics Financial Statement Overview
Summary
MiNK Therapeutics is experiencing significant financial challenges, with consistently negative revenue, high net losses, negative equity, and poor cash flow management. The company faces high leverage and lacks revenue growth, highlighting substantial operational and financial risks.Income Statement
MiNK Therapeutics shows consistently negative revenue and high net losses, indicating poor financial performance. The company lacks revenue growth, with negative gross profit margins and no clear path to profitability. Revenue growth is absent, and all profitability margins are negative, highlighting significant operational challenges.15
Very Negative
Balance Sheet
The company's balance sheet reveals high liabilities relative to negative equity, indicating financial instability. A negative debt-to-equity ratio and a negative equity ratio suggest substantial risks. Despite some cash reserves, the overall financial health is weak with high leverage.20
Very Negative
Cash Flow
MiNK Therapeutics exhibits negative operating and free cash flows, indicating poor cash management. The operating cash flow to net income ratio is high but negative, suggesting inefficiencies in cash generation relative to its income. Free cash flow growth is absent, reflecting cash flow challenges.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| -11.71B | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K | Gross Profit |
| -13.59B | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K | EBIT |
| -14.29M | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M | EBITDA |
| -13.90M | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M | Net Income Common Stockholders |
| -13.78M | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 299.04K | 3.37M | 19.64M | 38.89M | 2.69M | 299.04K | Total Assets |
| 0.00 | 4.55M | 21.47M | 40.24M | 4.56M | 1.31M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 43.82M | 26.79M | Net Debt |
| 299.04K | -3.37M | -19.64M | -38.89M | 41.13M | 26.49M | Total Liabilities |
| 0.00 | 22.61M | 21.87M | 16.47M | 58.43M | 37.64M | Stockholders Equity |
| -36.33M | -18.06M | -401.30K | 23.78M | -53.87M | -36.33M |
| Cash Flow | Free Cash Flow | ||||
| -10.79M | -15.84M | -19.12M | -13.08M | -8.43M | -15.37M | Operating Cash Flow |
| -10.86M | -15.76M | -18.87M | -12.83M | -8.34M | -14.94M | Investing Cash Flow |
| -73.49M | -73.56K | -250.05K | -248.98K | -95.21K | -426.47K | Financing Cash Flow |
| 10.82M | -407.17K | -155.60K | 49.26M | 11.11M | 11.44M |
MiNK Therapeutics Technical Analysis
Negative
7.98
Price Trends
8.89
Negative
7.83
Positive
8.18
Negative
Market Momentum
-0.33
Positive
43.30
Neutral
25.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Negative. The current price of 7.98 is below the 20-day moving average (MA) of 8.93, below the 50-day MA of 8.89, and below the 200-day MA of 8.18, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 43.30 is Neutral, neither overbought nor oversold. The STOCH value of 25.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INKT.
MiNK Therapeutics Risk Analysis
MiNK Therapeutics disclosed 76 risk factors in its most recent earnings report. MiNK Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MiNK Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
44 Neutral | $118.14M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $37.60M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $115.74M | ― | -54.21% | ― | -78.55% | -0.92% | |
42 Neutral | $531.13M | ― | -17.48% | ― | ― | ― | |
40 Underperform | $30.95M | ― | 78.50% | ― | ― | 46.74% |
* Healthcare Sector Average
Performance Comparison
INKT
MiNK Therapeutics
7.98
-0.96
-10.74%
BLUE
Bluebird Bio
3.73
-24.67
-86.87%
FATE
Fate Therapeutics
0.94
-6.55
-87.45%
ADAP
Adaptimmune Therapeutics
0.45
-1.03
-69.59%
IMTX
Immatics
4.52
-7.49
-62.36%
MiNK Therapeutics Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: 0.50% | Next Earnings Date: Mar 18, 2025
Earnings Call Sentiment Positive
The earnings call reflected a generally positive outlook with significant advancements in clinical trials, efficient cost management, and promising data presentations at SITC. However, concerns about the cash position and early stages of the GVHD program indicate areas that require attention.Highlights
Operating Efficiency and Cost Reduction
MiNK Therapeutics achieved a 60% reduction in operating burn compared to the previous year, alongside improvements in manufacturing efficiencies that reduced cost of goods and increased production capacity.
Advancements in Clinical Programs
Progress in the Phase II trial for second-line advanced gastric cancer at Memorial Sloan-Kettering Cancer Center with promising efficacy signals. Additionally, advancements in the PRAME-TCR IND program were highlighted.
Strategic Leadership Addition
Dr. Robert Kadlec joined the Board of Directors, bringing expertise in public health and biodefense, expected to provide strategic value as MiNK expands its iNKT cell platform.
Positive Preclinical and Clinical Data
At the SITC meeting, data showed durable disease control with agenT-797 in heavily pretreated solid tumor patients, and its combination with bispecific engagers demonstrated increased tumor cell killing.
Financial Discipline
Significant reduction in cash used in operations to $3 million for Q3 2024 from $7.8 million in Q3 2023, with a net loss reduction to $1.8 million from $5.1 million year-over-year.
Lowlights
Cash Position Concerns
MiNK ended the quarter with a cash balance of $6.3 million, highlighting the need for strategic initiatives to strengthen financial resources.
Graft-Versus-Host Disease Program Still in Early Phases
The GVHD program is still in the activation phase with ongoing preclinical investigations, indicating that it may take time before reaching clinical milestones.
Company Guidance
During the MiNK Therapeutics Q3 2024 earnings call, the company highlighted significant advancements and strategic initiatives, focusing on its iNKT cell therapy platform. Key metrics discussed included a nearly 60% reduction in operating burn from the previous year, achieved through external funding and manufacturing efficiencies. The financials revealed a cash balance of $6.3 million at the end of the quarter, with a net loss of $1.8 million for the three months ending September 2024, compared to $5.1 million for the same period in 2023. The company is progressing with its Phase II trial for advanced gastric cancer, with enrollment expected to complete by mid-next year and plans for a data update in early 2025. Additionally, ongoing efforts in reducing the costs associated with manufacturing, along with strategic partnerships, are aimed at bolstering financial discipline and enhancing clinical outcomes.MiNK Therapeutics Corporate Events
Executive/Board Changes
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board
Neutral
Oct 31, 2024
MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.